Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?

If you are wondering whether AstraZeneca at £136.32 is still offering value after a strong run, the key question is how its ...

AstraZeneca’s Elecoglipron Advances To Phase 3 And Expands Pipeline Potential

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.
Bloomberg L.P.

Drugmaker AstraZeneca’s Market Value Soars Past £200 Billion

AstraZeneca Plc’s market value surged above £200 billion ($257 billion) for the first time after a big bet on cancer drugs helped drive a rally in the shares. Shares climbed as much as 0.5% on ...
Morningstar

AstraZeneca: Investor Day Reveals Optimistic 2030 Sales Guidance, but Pipeline Holds Possible Upside

We are holding steady to our AstraZeneca fair value estimate following an investor day, which highlighted 2030 sales guidance of $80 billion and 2026 core operating margins of mid-30s. While we ...
Nasdaq

Why AstraZeneca Topped the Market on Thursday

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the ...